Artificial disruption of CCR5 became a promising method to generate resistance to HIV-1 infection (see below) and the application of the CRISPR/Cas9 technology for that purpose is currently tested in a clinical trial (Hu, C. Safety of transplantation of CRISPR CCR5 modified CD34+ cells in HIV-infected subjects with hematological malignances. This evidence concerns the gene CCR5 and HIV-1 infection.